Merck报告收入丰厚、股息增高、财政稳定, Merck reports strong earnings, raises dividend, and maintains solid finances despite executive share sale.

Merck & Co.报告最近季度每股1.94美元的收入,机构投资者,包括河谷国家顾问和Thompson投资管理公司,增加了股份。 Merck & Co. reported $1.94 earnings per share for its latest quarter, with institutional investors increasing their stake, including Valley National Advisers and Thompson Investment Management. 该公司将季度红利提高到0.85美元,达到3.2%,并保持强劲的财政状况,股本回报率为44.54%,债务与股本比率为0.77。 The company raised its quarterly dividend to $0.85, yielding 3.2%, and maintains a strong financial profile with a 44.54% return on equity and a debt-to-equity ratio of 0.77. 分析员持有一致的“等待”评级,平均价格目标为110.13美元。 Analysts hold a consensus "Hold" rating with a $110.13 average price target. Merck是全球生物制药领头人,重点研究肿瘤学、疫苗和慢性病,主要产品如Keyturda和Gardasil。 Merck, a global biopharmaceutical leader, focuses on oncology, vaccines, and chronic diseases, with key products like Keytruda and Gardasil. 执行官David Michael Williams出售了8 614股股票,将股份减少了25.95%。 Executive David Michael Williams sold 8,614 shares, reducing his stake by 25.95%.